Sign inJoin waitlistJoin the waitlist

Andrew Sharabi

Jacobs Chancellor’s Endowed Chair in Radiation Medicine and Applied Sciences · University of California (San Diego) Medical Center

Credentials: · · · · · ·

History

Radiation Oncology
Johns Hopkins University School of Medicine
2011–2015
Preliminary or Transitional Year
2010–2011
University of California San Diego 2001
Baylor College of Medicine
2006–2010

Research

Radiation and checkpoint blockade immunotherapy: radiosensitisation and potential mechanisms of synergy
Review · The Lancet Oncology · 2015 · First of 4 authors · Corresponding · 766 citations
Hyperprogressors after Immunotherapy: Analysis of Genomic Alterations Associated with Accelerated Growth Rate
Clinical Cancer Research · 2017 · 730 citations
Stereotactic Radiation Therapy Augments Antigen-Specific PD-1-Mediated Antitumor Immune Responses via Cross-Presentation of Tumor Antigen
Cancer Immunology Research · 2015 · First of 8 authors · 558 citations

Loren Mell
16 papers
Joseph Califano
14 papers
Sangwoo Kim
12 papers · 7 as a resident
Ezra Cohen
11 papers
James Murphy
8 papers
CD
Charles Drake
7 papers
Robert Saddawi-Konefka
6 papers · 3 as a resident
Whitney Sumner
6 papers · 6 as a resident
Jyoti Mayadev
5 papers
Kripa Guram
5 papers · 3 as a resident
Razelle Kurzrock
5 papers
Ajay Sandhu
4 papers

Grants

Investigating the Role of B-Cells in Durable Complete Responses to Immunotherapy in Head and Neck Cancer
National Cancer Institute · R01
Contact PI · $650.6K · University of California, San Diego
2026–2031
Optimizing Immunoradiotherapy for HNSCC
National Cancer Institute · R01
PI · $2.7M · University of California, San Diego
2023–2028
Role of B-Cell Mediated Anti-Tumor Antibodies in Responses to Radiation and Immunotherapy in HNSCC
National Institute of Dental and Craniofacial Research · R01
Contact PI · $1.8M · University of California, San Diego
2019–2024
Investigating Mechanisms of Hyperprogression on Anti-PD-1 Immunotherapy
National Cancer Institute · R21
Contact PI · $401.5K · University of California, San Diego
2021–2022

Clinical trials

SBRT Combined With Avelumab (Anti-PD-L1) for Management of Early Stage Non-Small Cell Lung Cancer (NSCLC)
Principal investigator · Terminated · Phase 1, Phase 2
Andrew Sharabi
2017–2019
Checkpoint Blockade Immunotherapy Combined With Stereotactic Body Radiation in Advanced Metastatic Disease
Principal investigator · Completed · Phase 2
University of California, San Diego
2016–2024